Skip to main content

TYVASO DPI IS NOW APPROVED

Learn more

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

SELECT INDICATION
Request a Rep

Patient Support

ACCESS AND FINANCIAL ASSISTANCE arrow-down ARCHWAYS PROGRAM arrow-down CO-PAY ASSISTANCE PROGRAM arrow-down
  • The program is offered to eligible patients at no cost for up to 90 days
  • Your patients have no obligation to continue taking TYVASO DPI at the end of the trial period
  • Eligibility for this program is limited to patients with PAH (WHO Group 1) or PH-ILD (WHO Group 3). This program is not valid for: patients currently using TYVASO DPI, Orenitram® (treprostinil) Extended-Release Tablets, TYVASO® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection; patients who previously used TYVASO DPI outside of the hospital setting; patients currently on an inhaled, oral, or infused prostacyclin. For other eligibility criteria, see full Terms and Conditions on the Enrollment Form
DOWNLOAD 90-DAY TRIAL FORM
TYVASO DPI 90-Day Trial Program

ACCESS AND FINANCIAL ASSISTANCE

ASSIST (Access Solutions and Support Team)

  • Reimbursement specialists help patients determine whether they qualify for United Therapeutics’ patient assistance programs
  • Making sure all necessary information for referrals has been provided
  • Information for healthcare professionals is available at www.UTassist.com
ASSIST (Access Solutions and Support Team) logo

A Virtual Patient Educator is available to help your patients get started with TYVASO

Managing Pulmonary Arterial Hypertension (PAH) and getting started on treatment with TYVASO (inhaled treprostinil) can leave patients with questions. The United Therapeutics’ Archways program is here to help.

The United Therapeutics’ Archways program is a virtual, educational support program that offers helpful disease information and resources for treatment. Archways is available at no cost to patients and caregivers as they begin their treatment journey with TYVASO.

Patients will connect one-on-one with an Archways Virtual Patient Educator to learn more about their condition and what to expect with their newly prescribed treatment.

To get started, patients may follow one of these three simple steps:

United Therapeutics and the Archways program do not provide medical advice. Patients are advised to consult with their HCP with any specific questions or concerns about their treatment.

archways logo

CO-PAY ASSISTANCE PROGRAM

MOST ELIGIBLE PATIENTS PAY AS LITTLE AS A $0 CO-PAY FOR EACH PRESCRIPTION OF TYVASO OR TYVASO DPI

This program is valid only for the cost of the drug TYVASO or TYVASO DPI and not applicable to any related supplies or other medical expenses associated with administering the product.

The patient will be responsible for any remaining balance that is not covered by their initial $0 co-pay and the maximum program benefit.

Most eligible TYVASO patients who enroll may pay as little as a $0 co-pay per prescription

PATIENT TERMS AND CONDITIONS

To enroll in the TYVASO Co-Pay Assistance Program, your patients must understand and agree that they currently meet the eligibility criteria and will comply with the Terms and Conditions described below:

  • The Program is valid only for patients with commercial (also known as private) insurance who are taking the medication for an FDA-approved indication.

  • Patients using Medicare, Medicaid, or any other state or federal government program to pay for their medications are not eligible. Patients who start utilizing government coverage during the term of the Program will no longer be eligible. Eligible patients must be a resident of the US or Puerto Rico.

  • The Program is subject to additional state law restrictions. Patients residing in select states may not be eligible for the Program.

  • This Program is valid only for the cost of the drug and not applicable to any related supplies or other medical expenses associated with administering the product. This Program is not conditioned on any past, present, or future purchase, including refills.

  • Void where prohibited, taxed, or restricted by law.

  • The patient confirms that this Program is consistent with patient’s insurance. The patient is responsible for reporting the receipt of all Program benefits as required by the insurance company.

  • This Program is not insurance and is not intended to substitute for insurance.

  • Limit 1 (one) Program ID number per patient.

  • This ID number is non-transferable and has no value.

  • Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer.

  • United Therapeutics reserves the right to modify or terminate this Program at any time without notice.

  • By enrolling in the Program, you agree that your personal information may be used by United Therapeutics and its affiliates to send you information about United Therapeutics products, programs, support, and services related to your condition and contact you in connection with your participation in the Program and as provided in our Privacy Policy. United Therapeutics respects the privacy of your personal information and you may unsubscribe from our programs at any time by calling ASSIST at 1-877-UNITHER (1-877-864-8437).

    For full program details and Terms and Conditions, visit www.UTcopay.com.